{"schema_version":"secwatch.filing_event.v1","accession":"0001534120-26-000042","form_type":"8-K","ticker":"AVTX","cik":"0001534120","company_name":"Avalo Therapeutics, Inc.","filed_at":"2026-06-16T11:18:22+00:00","discovered_at":"2026-06-16T11:20:00.296163+00:00","generated_at":"2026-06-16T11:20:09.007524+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Avalo Therapeutics expands pipeline with AVTX-010, a long-acting anti-IL-1β mAb; IND planned H1 2027","bullets":["AVTX-010 is an engineered anti-IL-1β mAb for hidradenitis suppurativa and other inflammatory disorders.","IND submission for AVTX-010 expected in the first half of 2027.","Building on abdakibart Phase 2 LOTUS data and the IL-1β pathway conviction.","CEO cites less frequent dosing as key driver for physician and patient preference.","Follows transformational financing completed in May 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001534120-26-000042","json":"https://secwatch.observer/filing/0001534120-26-000042.json","markdown":"https://secwatch.observer/filing/0001534120-26-000042.md","text":"https://secwatch.observer/filing/0001534120-26-000042.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534120/000153412026000042/0001534120-26-000042-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534120/000153412026000042/avtx-20260616.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T11:20:09.007524+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}